Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne dis
The FDA has approved Takeda’s Fruzaqla for a group of patients with relapsed or refractory metastatic colorectal cancer, offering another option for patients who have exha
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a
MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch
Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th
After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.